explore -WSS

explore

author：knowledge 2025-08-23 08:56:47 - browse：1184

Matts Take Column Illustration — Molly Ferguson for STAT

What do you say to a patient when the FDA rejects “their” experimental drug — one that they believe can alleviate at least some of their suffering?

That question arises in the aftermath of a dramatic moment at the Food and Drug Administration last week. Over the FDA’s protests, a small biotechnology company called BrainStorm Cell Therapeutics had insisted that the agency evaluate its experimental treatment for amyotrophic lateral sclerosis, or ALS, brand named NurOwn. ALS patients made fervent pleas for the medicine, a type of stem cell preparation, based on reports on social media and re-analyses of the data that they thought indicated it might be of some help to those with the fatal disease.

But the FDA methodically dismantled BrainStorm’s application. The medicine couldn’t work the way the company said it would, the agency insisted; the clinical trials didn’t show it was effective; and it was not clear BrainStorm could manufacture the medicine with sufficient quality. Worst of all, more patients died among those who received the drug than those who got placebo. The FDA’s panel of expert advisers voted 17 to 1 that the medicine was not safe and effective, with one person abstaining. The agency doesn’t have to follow the panel’s advice but probably will.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： A Q&A with Aletha Maybank, AMA’s chief health equity officer

Wikipedia

WSS

FogPharma raises $145 million in rare Series E round

Pfizer highlights cancer drugs it thinks could reignite investor interest

How to fix the rural physician shortage in the U.S.

How to fix the rural physician shortage in the U.S.

Why getting cancer drugs just got harder for rural patients

House looks to weaken Medicare negotiation

entertainment

explore

leisure time

In Memoriam: Notable people who died in 2023

An inside look at PIPEs, biotech's buzzy new financing tool

BioMarin wins approval for gene therapy to treat hemophilia A

Congress gives doctors Medicare pay bump

Activists slam private health insurers over coverage restrictions

Medical device lobby: We're tired of waiting on Medicare coverage

FDA approval of Sarepta Duchenne genetic therapy gives me hope

ALS groups 'won't be played again' by the FDA, drug sponsors

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Congress gives doctors Medicare pay bump

hotspot

Kenai launches with $82 million for Parkinson’s stem cell therapy

Clinical trials giant ICON acquires HumanFirst

Change Healthcare cyberattack outage could last weeks

Congress gives doctors Medicare pay bump

RSV vaccines may be linked to small increased risk of developing GBS

ALS groups 'won't be played again' by the FDA, drug sponsors

focus

focus

Wikipedia

entertainment